Title: Title# Defibrotide improved outcome of monocrotaline induced rat hepatic sinusoidal
obstruction syndrome
Version: 2 Date: 21 Jun 2022
Reviewer:  Shohei Yamamoto
Reviewer's report:
The authors described defibrotide improved new rat HSOS model using monocrotaline.
Although the paper was well written and organized experiment, some date were obscure.
1. The authors described the survival rate were significantly lower in defibrotide group (81.9%)
than model group (43.7%). Is that correct?  I think "higher" instead on "lower".   Defibrotide
improved the cure rate.
2. Group A, B,  C, D, E were described in Fig3. But, figure legends were Group1, 2,3,4,5.
Which was correct?
3. Did you analyze the combined group which was including LMWH and defibrotide?
4. We want to know what is the advantages this rat model than that of actual SCT model rat?
Would you please mention that in discussion part?
Title: Title# Defibrotide improved outcome of monocrotaline induced rat hepatic sinusoidal
obstruction syndrome
Version: 2 Date: 21 Jun 2022
Reviewer:  Shohei Yamamoto
Reviewer's report:
The authors described defibrotide improved new rat HSOS model using monocrotaline.
Although the paper was well written and organized experiment, some date were obscure.
1. The authors described the survival rate were significantly lower in defibrotide group (81.9%)
than model group (43.7%). Is that correct?  I think "higher" instead on "lower".   Defibrotide
improved the cure rate.
2. Group A, B,  C, D, E were described in Fig3. But, figure legends were Group1, 2,3,4,5.
Which was correct?
3. Did you analyze the combined group which was including LMWH and defibrotide?
4. We want to know what is the advantages this rat model than that of actual SCT model rat?
Would you please mention that in discussion part?
Please review this paper.
user
Title: Title# Defibrotide improved outcome of monocrotaline induced rat hepatic sinusoidal
obstruction syndrome
Version: 2 Date: 21 Jun 2022
Reviewer:  Shohei Yamamoto
Reviewer's report:
The authors described defibrotide improved new rat HSOS model using monocrotaline.
Although the paper was well written and organized experiment, some date were obscure.
1. The authors described the survival rate were significantly lower in defibrotide group (81.9%)
than model group (43.7%). Is that correct?  I think "higher" instead on "lower".   Defibrotide
improved the cure rate.
2. Group A, B,  C, D, E were described in Fig3. But, figure legends were Group1, 2,3,4,5.
Which was correct?
3. Did you analyze the combined group which was including LMWH and defibrotide?
4. We want to know what is the advantages this rat model than that of actual SCT model rat?
Would you please mention that in discussion part?
assistant